You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

A different mechanism of action


Keppra is a broad spectrum AED with a different mechanism of action1

Mechanisms of action of AEDs1,2

Close to the ideal pharmacokinetic profile for an AED

Keppra’s pharmacokinetic profile closely approximates the optimal characteristics expected for an AED3-6


Keppra’s pharmacokinetic profile3,5

* Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Keppra: Mechanism of action video

Video player requires JavaScript enabled. You can download this video here: # # #

Read more about Keppra

Abbreviations

AED: anti-epileptic drug; BZD: benzodiazepines; Ca: calcium; CBZ: carbamazepine; ESL: eslicarbazepine; GABA: gamma-aminobutyric acid; GBP: gabapentin; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine; Na: sodium; OXC: oxcarbazepine; PB: phenobarbital; PER: perampanel; PHT: phenytoin; SV2A: synaptic vesicle protein 2A; TIG: tiagabine; TOP: topiramate; VPA: valproate; ZNS: zonisamide. 

References

  1. Sills GJ. Mechanisms of action of antiepileptic drugs. Available at: https://www.epilepsysociety.org.uk/sites/default/files/attachments/Chapter25Sills2015.pdf. Accessed April 2020.
  2. Lyseng-Williamson KA. Drugs 2011;71(4):489–514.
  3. Levetiracetam. Non Central Data Sheet Version Number: 10. Version Date: 6 January 2020.
  4. Panayiotopoulos CP. Oxfordshire (UK): Bladon Medical Publishing; 2005. Chapter 4 Principles of Therapy in Epilepsies. Available at: https://www.ncbi.nlm.nih.gov/books/NBK2606/. Accessed April 2020.
  5. Patsalos PN. Pharmacol Ther 2000;85(2):77–85. 
  6. Lyseng-Williamson KA. CNS Drugs 2011;25(10):901–905.

GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein. 
For safety information on GSK products or to report an Adverse Event, please contact the toll free line 
0800 CALL GSK (0800 2255 475) or email aereporting.ng@gsk.com 
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact 
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at customercare_ph_nigeria@gsk.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000 
©2020 GSK group of companies or its licensor 
Trade marks are owned by or licensed to the GSK group of companies

Keppra is a registered trademark of the GlaxoSmithKline group of companies

PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.